Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer

BACKGROUND/AIMS: Programmed death-ligand 1 (PD-L1) expression, a validated predictive biomarker for anti-PD-1/PD-L1 inhibitors, is reported to change over time. This poses challenges during clinical application in non-small cell lung cancer. METHODS: This study included patients with non-small cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, Chang Hyun, Koh, Jaemoon, Ock, Chan-Young, Kim, Miso, Keam, Bhumsuk, Kim, Tae Min, Jeon, Yoon Kyung, Kim, Dong-Wan, Chung, Doo Hyun, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273838/
https://www.ncbi.nlm.nih.gov/pubmed/32872743
http://dx.doi.org/10.3904/kjim.2020.178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273838/
https://www.ncbi.nlm.nih.gov/pubmed/32872743
http://dx.doi.org/10.3904/kjim.2020.178

Ejemplares similares